Finance

Lists
Q3 2026 earnings • in 4 days
See details
INSM:NASDAQ
Insmed Inc
$93.39
-1.76%
(-1.67) 1D
$93.39
0.00% (0.00)
After hours
Closed: Oct 23, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INSM...
Open
$94.12
High
$94.64
Low
$92.62
Mkt. cap
20.39B
Avg. vol.
2.70M
Volume
3.41M
52-wk high
$212.75
52-wk low
$90.39
EPS
-$4.10
Beta
0.83
Shares outstanding
218.38M
No. of employees
2K
Open
$94.12
High
$94.64
Low
$92.62
Mkt. cap
20.39B
Avg. vol.
2.70M
Volume
3.41M
52-wk high
$212.75
52-wk low
$90.39
EPS
-$4.10
Beta
0.83
Shares outstanding
218.38M
No. of employees
2K
News stories
From web sources and news partners
About Insmed Inc
CEOWilliam H. Lewis
Employees1.66K
Founded1988
HeadquartersBridgewater, New Jersey, United States
SectorBiotechnology
Websiteinsmed.com
Analyst ratings
Based on 21 analysts giving stock ratings to INSM in the past 3 months
Strong buy
Buy
20
Hold
1
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for INSM in the last 3 months.
Highest
Current $93.39
$243.00 (+160.20%)
Average
$196.16 (+110.04%)
Lowest
$169.00 (+80.96%)
Analyst
Recommendation
Action
Price target
Projected
Date
Maxwell Skor
Morgan Stanley
Buy
Reiterated
$213.00
+128.1%
10/21/2026
Adam Walsh
Roth MKM
Buy
Reiterated
$198.00
+112%
10/20/2026
Tiago Fauth
Raymond James
Buy
Maintained
$173.00
+85.2%
10/20/2026
Benjamin Burnett
Wells Fargo
Buy
Reiterated
$169.00
+81%
10/13/2026
Conor MacKay
BMO Capital
Buy
Maintained
$192.00
+105.6%
10/12/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$220.00
+135.6%
10/12/2026
Jason Zemansky
Bank of America Securities
Buy
Reiterated
$207.00
+121.7%
10/12/2026
Andy Chen
Wolfe Research
Hold
Downgraded
-
-
10/12/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$195.00
+108.8%
10/08/2026
Ashwani Verma
UBS
Buy
Maintained
$172.00
+84.2%
10/07/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$195.00
+108.8%
10/05/2026
Eliana Merle
Barclays
Buy
Maintained
$207.00
+121.7%
09/30/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
$175.00
+87.4%
09/28/2026
Andrea Newkirk
Goldman Sachs
Buy
Initiated
$188.00
+101.3%
09/24/2026
Danielle Brill
Truist Financial
Buy
Reiterated
$195.00
+108.8%
08/10/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
$235.00
+151.6%
08/06/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$170.00
+82%
08/07/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$205.00
+119.5%
08/06/2026
Ritu Baral
TD Cowen
Buy
Maintained
$243.00
+160.2%
08/06/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$175.00
+87.4%
08/06/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
08/06/2026
Evan Seigerman
BMO Capital
Buy
Initiated
$192.00
+105.6%
07/21/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$192.00
+105.6%
07/20/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$200.00
+114.2%
07/17/2026
Unknown Analyst
Jefferies
Buy
Maintained
$175.00
+87.4%
06/23/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$243.00
+160.2%
05/20/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$180.00
+92.7%
05/20/2026
Unknown Analyst
Evercore ISI
Buy
Maintained
$162.00
+73.5%
05/15/2026
Unknown Analyst
Raymond James
Buy
Initiated
$200.00
+114.2%
04/09/2026
Next call in 4 days
Thu, Oct 29, 8:00 AM
Fiscal period
Q3 2026
- / -$0.38
Revenue / Est. (USD)
- / 499.48M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
142.34M
263.84M
305.96M
425.49M
Cost of goods sold
29.36M
44.22M
47.42M
67.21M
Cost of revenue
29.36M
44.22M
47.42M
67.21M
Research and development expenses
186.42M
254.91M
209.48M
210.03M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
186.38M
212.48M
247.26M
247.47M
Operating expense
374.33M
469.33M
458.82M
459.58M
Total operating expenses
403.69M
513.55M
506.24M
526.79M
Operating income
-261.35M
-249.71M
-200.28M
-101.31M
Other non operating income
-603.00K
-1.82M
-736.00K
-531.00K
EBT including unusual items
-368.70M
-326.93M
-162.10M
-11.37M
EBT excluding unusual items
-264.05M
-256.89M
-209.06M
-111.13M
Income tax expense
1.32M
1.55M
1.46M
1.87M
Effective tax rate
-0.36%
-0.47%
-0.90%
-16.43%
Other operating expenses
-
-
-
-
Net income
-370.02M
-328.48M
-163.56M
-13.24M
Net profit margin
-259.95%
-124.50%
-53.46%
-3.11%
Earnings per share
-1.75
-1.54
-0.76
-0.06
Interest and investment income
18.29M
15.24M
12.04M
10.98M
Interest expense
-20.38M
-20.60M
-20.08M
-20.27M
Net interest expenses
-2.09M
-5.36M
-8.04M
-9.29M
Depreciation and amortization charges
-
-
-
-
EBITDA
-257.89M
-244.68M
-195.80M
-96.58M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps